The Motley Fool·5d ago
Why Indivior Pharmaceuticals Stock Topped the Market TodayThe peer is Supernus Pharmaceuticals. The combined business will bear the Supernus name and stock ticker under the terms of a deal announced in August.
Indivior's injectable franchise has driven revenue from $317.0M in 2026Q1 to $356.0M in 2026Q3 (13.4% year-over-year), with gross margins holding near 85.7% and operating margin expanding from 23.8% in 2025Q2 to 50.8% in 2026Q3, which suggests a durable profitability turn.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $1.32+24.5% vs $1.06 | $356M+8.1% vs $329M |
Q3 2026 Aug 3, 2026 | $1.15+32.3% vs $0.87 | $343M+12.0% vs $306M |
Q2 2026 Apr 30, 2026 | $0.96+50.0% vs $0.64 | $317M+16.2% vs $273M |
Q1 2026 Feb 26, 2026 | $0.82+26.2% vs $0.65 | $358M+17.1% vs $306M |
The peer is Supernus Pharmaceuticals. The combined business will bear the Supernus name and stock ticker under the terms of a deal announced in August.
Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record Non-GAAP Net Income of $ 161 Million in Q3'26 Record Quarterly Adjusted EBITDA of $ 211 Million in Q3'26, Up 76% YoY Net Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA Margin of 59% , Up 2,100 Basis Points YoY On Track to Close Merger with Supernus on November 2nd RICHMOND, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2026.
Indivior (NASDAQ: INDV - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Indivior to post earnings of $1.06 per share and revenue of $329.35 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings report for the
RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will be released at 7:00 a.m. U.S. EDT and will be available on the Company's website at www.indivior.com.
Benchmark INDV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Indivior Pharmaceuticals Inc (INDV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $36.28 | $4.53B | 9.84 | 4.29% | 32.75% | — | — | |
| $1.35 | $237.79M | 12.99 | 1.28% | 2.32% | 4.51% | — | |
| $16.55 | $3.51B | 48.08 | 26.93% | 15.67% | 17.07% | — | |
| $14.48 | $2.18B | -4.03 | — | — | -2271.87% | — | |
| $45.90 | $7.7B | -9999.00 | -5.25% | -0.02% | -0.02% | — | |
| $8.18 | $3.06B | -3.70 | 6.66% | -7.57% | — | — |
Indivior Pharmaceuticals Inc (INDV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Indivior Pharmaceuticals Inc (INDV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 15, 2026·SEC
Oct 6, 2026·SEC
Get notified when INDV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Indivior Pharmaceuticals Inc (INDV) stock FAQ — growth, dividends, profitability & financials explained
Indivior Pharmaceuticals Inc (INDV) reported $1.37B in revenue over the trailing twelve months. Revenue was $1.24B in fiscal year 2025. That is 28% more than the $968.9M of fiscal year 2016.
Indivior Pharmaceuticals Inc (INDV) grew revenue by 16.3% over the trailing twelve months, compared with the twelve months before.
Yes. Indivior Pharmaceuticals Inc (INDV) earned $450.0M in net income over the trailing twelve months (a 32.8% net margin).
Indivior Pharmaceuticals Inc (INDV) generated $31.0M in free cash flow over the trailing twelve months.
